ighted-average sharesoutstanding (thousands) – diluted1,112,0261,103,406Eli Lilly and CompanyOperating Results (Unaudited) – Non-GAAP (Dollars in millions, except per share data)Three Months EndedMarch 312011(a)
2010(b)
% Chg.Total revenue
$
5,839.2
$
5,485.5
6%Cost of sales1,180.11,122.5
5%Research and development1,124.01,039.1
8%Marketing, selling and administrative1,785.71,614.4
11%Operating income 1,749.41,709.5
2%Net interest income (expense)(30.3)(37.0)Net other income (expense)19.1111.5Other income (expense)(11.2)74.5
NMIncome before income taxes1,738.21,784.0
(3)%Income taxes363.3486.4
(25)%Net income
$
1,374.9
$
1,297.6
6%Earnings per share – basic
$
1.24
$
1.18
5%Earnings per share – diluted
$
1.24
$
1.18
5%Dividends paid per share
$
0.49
$
0.49
NMWeighted-average sharesoutstanding (thousands) – basic1,112,0031,103,380Weighted-average sharesoutstanding (thousands) – diluted1,112,0261,103,406
- The first quarter 2011 has been adjusted to eliminate a restructuring charge of $76.3 million (pretax), or $0.06 (after-tax). This charge is related to severance costs from previously announced strategic actions that the company is taking to reduce its cost structure and global workforce. In addition, the first quarter 2011 financial statements have been adjusted to eliminate a charge of $388.0 million (pretax), or $0.23 per share (after-tax), for acquired in-process research and development associated with the collaboration with Boehringer Ingelheim.
- The first quarter 2010 has been adjusted to eliminate a restructuring charge of $26.2 million (pretax), or $0.02 (after-tax). This charge is primarily related to severance costs from prev
'/>"/>
SOURCE Eli Lilly and Company Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related medicine technology :1.
FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women2.
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer3.
Lilly and Glenmark Pharmaceuticals Announce License Agreement4.
Lilly Receives NCQA Design Certification for Depression Care Management Program5.
JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers6.
FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel7.
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release8.
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement9.
Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease10.
Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction11.
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration